Nektar Therapeutics (NKTR) Profit After Tax (2010 - 2026)

Nektar Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$44.9 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 11.75% year-over-year to -$44.9 million; the TTM figure through Mar 2026 stood at -$158.1 million (down 18.83% YoY), while the FY2025 annual figure was -$164.1 million, down 37.92% from the prior year.
• Profit After Tax was -$44.9 million for Q1 2026 at Nektar Therapeutics, down from -$36.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $7.3 million in Q4 2024 to a low of -$159.1 million in Q2 2022.
• Historically, Profit After Tax has averaged -$57.2 million across 5 years, with a median of -$45.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 117.26% in 2024, then plunged 596.89% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$59.7 million in 2022, then climbed by 29.5% to -$42.1 million in 2023, then jumped by 117.26% to $7.3 million in 2024, then slumped by 596.89% to -$36.1 million in 2025, then retreated by 24.46% to -$44.9 million in 2026.
• The last three Profit After Tax figures came in at -$44.9 million (Q1 2026), -$36.1 million (Q4 2025), and -$35.5 million (Q3 2025), per Business Quant data.